Log in to search using one of your social media accounts:

 

Promising Drug Reduces Growth of Aggressive Mesothelioma
Scientists in Italy have found a platinum-based drug that successfully lessens growth of the most aggressive type of mesothelioma cancer cells. Researchers at the University of Salento discovered the experimental drug Ptac2S was more effective in reducing the spread of sarcomatoid malignant pleural mesothelioma cells in mice compared to cisplatin — the most widely used chemotherapy drug for treating mesothelioma. Sarcomatoid is the least common of the three mesothelioma cell types but is considered more aggressive and harder to treat. A diagnosis with the sarcomatoid cell type is typically associated with a poor pro...
Source: Asbestos and Mesothelioma News - August 7, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Alimta alternatives to cisplatin Antonella Muscella Biphasic mesothelioma chemotherapy for mesothelioma chemotherapy resistance DNA adducts epithelioid mesothelioma genomic activities mesothelioma clinical trials mesothelioma survival Source Type: news

Not Legit? The Superiority of Pemetrexed in Lung Cancer Not Legit? The Superiority of Pemetrexed in Lung Cancer
Pemetrexed's reputation for superior efficacy in the initial treatment of lung cancer is based on less-than-definitive data but has resulted in high usage and sales.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded. Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma. The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledron...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news

UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents
INDIANAPOLIS, July 7, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of Alimta® (pemetrexed disodium) that ... Biopharmaceuticals, Litigation Eli Lilly, Actavis, Alimta, pemetrexed disodium (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 7, 2017 Category: Pharmaceuticals Source Type: news

UK Supreme Court rules in favor of Lilly's Alimta patents
(Reuters) - Eli Lilly and Co said on Friday the UK Supreme Court ruled that generic versions of the company's top-selling cancer drug Alimta sold by Actavis directly infringe certain Lilly patents in the UK, France, Italy and Spain. (Source: Reuters: Health)
Source: Reuters: Health - July 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Seattle Cancer Center Opens Latest Mesothelioma Clinical Trial
The Seattle Cancer Care Alliance has opened a phase II clinical trial involving durvalumab, the promising immunotherapy drug, in combination with chemotherapy for the first-line treatment of unresectable pleural mesothelioma. The U.S. Food and Drug Administration (FDA) already granted accelerated approval to durvalumab in May for the treatment of bladder cancer. Researchers have also lauded the drug for its effectiveness in earlier lung cancer clinical trials. “We have every reason to believe it will be effective with mesothelioma, too,” Dr. Bernardo Goulart, chief trial investigator and medical oncologist at t...
Source: Asbestos and Mesothelioma News - June 27, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: cancer in seattle doctor Bernardo Goulart mesothelioma clinical trials mesothelioma in seattle mesothelioma treatment seattle cancer care alliance Source Type: news

Nintedanib Combination Delayed Progression in Malignant Mesothelioma
Adding nintedanib to pemetrexed/cisplatin improved the progression-free survival of patients with malignant pleural mesothelioma compared with placebo. (Source: CancerNetwork)
Source: CancerNetwork - June 22, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Lung Cancer News Source Type: news

Mesothelioma Clinical Trial Opens with High Expectations
Newly diagnosed mesothelioma patients around the world have begun enrolling in a much-anticipated, phase III clinical trial involving an immunotherapy drug combination with groundbreaking potential. The trial, designed as first-line therapy for unresectable pleural mesothelioma, will measure the effectiveness of nivolumab (Opdivo) and ipilimumab (Yervoy) against standard-of-care chemotherapy. A presentation this month at the 2017 American Society of Clinical Oncology (ASCO) annual meeting sparked high expectations for the trial, detailing early, impressive effectiveness involving the two drugs in second-line and third-lin...
Source: Asbestos and Mesothelioma News - June 16, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center American Society of Clinical Oncology Bristol-Myers Squibb cancer immunotherapy research cisplatin for mesothelioma Cleveland Clinic Cancer Center CRS-207 disease control rate Dr. Arnaud Scherpereel Dr. Patrick Ma Source Type: news

Genetic Biomarkers Key to Future Mesothelioma Treatment
Researchers in Slovenia have developed a unique, treatment-recommendation model for mesothelioma patients based heavily upon individualized, genetic biomarkers. They believe their model will lead to better patient outcomes and significantly improve the response rate to chemotherapy, which is still less than 40 percent with mesothelioma. “This is just a start, but it’s going to be the way to go in the future, personalizing treatment,” Dr. Vita Dolzan, founder of Pharmacogenetics Laboratory at the University of Ljubljana’s Institute of Biochemistry, told Asbestos.com. “We’re excited about ...
Source: Asbestos and Mesothelioma News - May 22, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Anhovo Asbestos Valley Slovenia chemotherapy drugs for mesothelioma cisplatin CRP protein Dr. Vita Dolzan gemcitabine genetic biomarkers genetic makeup mesothelioma patients Genotyping mesothelioma treatment strategies pemetrexed p Source Type: news

Latest Keytruda Approval Promising for Mesothelioma Patients
The U.S. Food and Drug Administration (FDA) expanded its approval of pembrolizumab for first-line treatment of metastatic non-small cell lung cancer last week, moving it closer to becoming a viable treatment option for patients with pleural mesothelioma. Pembrolizumab is marketed by Merck & Co. under the brand name Keytruda. It helps the body’s immune system detect and destroy cancer cells. The FDA approved its first-line use in combination with pemetrexed and carboplatin, two chemotherapy agents used regularly for mesothelioma. Pembrolizumab, the most well-known immunotherapy drug, is being studied for use with...
Source: Asbestos and Mesothelioma News - May 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: carboplatin chemotherapy for mesothelioma Dr. Raymond Wong Dr. Tawee Tanvetyanon FDA approval Keytruda first line treatment for mesothelioma Hodgkin lymphoma jimmy carter keytruda clinical trial keytruda for mesothelioma melanoma Mer Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression
Dateline City: KENILWORTH, N.J. First Approval for an Anti-PD-1 Therapy as a Combination in Metastatic Nonsquamous NSCLCKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta®) and carboplatin (pem/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression.Language: ...
Source: Merck.com - Product News - May 10, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

Case Report Explores Benefits of Alimta as Second-Line Mesothelioma...
A Croatian man with advanced peritoneal mesothelioma lived for more than four years when treated with pemetrexed after relapse.(PRWeb May 09, 2017)Read the full story at http://www.prweb.com/releases/2017/05/prweb14316001.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 9, 2017 Category: Pharmaceuticals Source Type: news

New Mesothelioma Clinical Trial for Pleural, Peritoneal Patients
Pleural and peritoneal mesothelioma patients are eligible for a new clinical trial that combines the latest antibody-drug conjugate with standard-of-care chemotherapy at the Ochsner Medical Center in New Orleans. The drug, anetumab ravtansine (BAY 94-9343), is the highly touted conjugate that mixes immunotherapy with cytotoxic therapy and targets mesothelin, the tumor surface protein found in 85-90 percent of mesothelioma cancer patients. The Ochsner trial, which is currently recruiting participants, is the first time researchers will administer anetumab ravtansine in a first-line setting for mesothelioma. “It’...
Source: Asbestos and Mesothelioma News - April 28, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: anetumab ravtansine mesothelioma chemotherapy mesothelioma clinical trial new mesothelioma treatment ochsner clinical trial Source Type: news

Pemetrexed cost effective with assistance program in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 31, 2017 Category: Drugs & Pharmacology Source Type: news

Eli Lilly Beats Teva Appeal on Generic Cancer Drug
Eli Lilly blocks Teva from selling a generic equivalent of its lung cancer drug Alimta (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 13, 2017 Category: Pharmaceuticals Source Type: news

Sugarbaker Touts New Clinical Study for Mesothelioma Patients
This study expands on what we already know about surgery and chemotherapy for mesothelioma, and combines them in a new way…with the goal of reducing recurrence rates and improving survival and quality of life,” Groth said in a press release from the Baylor Medical Center. “The heated chemotherapy fluid is effective at killing cancer and making the chemotherapy work better.” Baylor also has other ongoing mesothelioma clinical trials: A phase II study of anetumab ravtansine for patients with unresectable pleural mesothelioma and high expression of mesothelin, a vulnerable, tumor-surface protein link...
Source: Asbestos and Mesothelioma News - December 22, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: baylor college of medicine chemotherapy for mesothelioma dr. david sugarbaker mesothelioma chemotherapy drugs mesothelioma clinical trial mesothelioma treatment center at baylor Source Type: news

Mesothelioma Trial for Nintedanib Shows Positive Results
Researchers have reported more promising results from an international, multicenter phase II clinical trial of the drug nintedanib, moving it another step closer to standard-of-care treatment for pleural mesothelioma. Nintedanib is a small-molecule enzyme inhibitor being studied as a way to increase the effectiveness of chemotherapy on mesothelioma and certain types of lung cancer. Researchers presented the results earlier this month at the World Conference on Lung Cancer in Vienna, Austria. The randomized clinical trial treated mesothelioma patients with a placebo and chemotherapy (pemetrexed/cisplatin) or nintedanib and ...
Source: Asbestos and Mesothelioma News - December 22, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma extending mesothelioma survival mesothelioma treatment nintedanib Source Type: news

Study Shows Impact of Chemotherapy on Mesothelioma
A U.S.-based study confirms what oncology experts have suggested for years — chemotherapy treatment prolongs life expectancy for malignant mesothelioma patients. Wayne State University School of Medicine researchers linked data from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database with Medicare claims data. The study took into account patient characteristics such as age, gender and amount of asbestos exposure. Not only did the findings show mesothelioma patients who have chemotherapy live longer, but it also proved multimodal therapy increases survival even more. The s...
Source: Asbestos and Mesothelioma News - December 19, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma doctor shirish gadgeel first line treatment for mesothelioma Human Investigation Committee at Wayne State mesothelioma diagnosis peritoneal mesothelioma wayne state university Source Type: news

Predictors of Chemotherapy Efficacy in NSCLC Predictors of Chemotherapy Efficacy in NSCLC
Can biomarkers predict the efficacy of conventional chemotherapy, such as gemcitabine and pemetrexed, for treatment of NSCLC?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Adding Pemetrexed to Gefitinib Improves PFS in EGFR-Mutated NSCLC
The combination of pemetrexed and gefitinib offered improved progression-free survival in East Asian patients with advanced nonsquamous NSCLC and activating EGFR mutations. (Source: CancerNetwork)
Source: CancerNetwork - August 8, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

New Mesothelioma Treatment Guidelines May Extend Survival
The National Comprehensive Cancer Network (NCCN) has changed its first-line treatment recommendation for unresectable pleural mesothelioma, believing it will extend patient survival significantly. The NCCN advisory panel recently added the monoclonal antibody bevacizumab to the long-standing chemotherapy combination of pemetrexed and cisplatin. Bevacizumab, also known by brand name Avastin, inhibits the formation of new blood vessels in tumors, effectively slowing the growth of cancer cells. It has successfully treated some types of lung and colorectal cancers. The NCCN recommendation is expected to be a precursor to the U...
Source: Asbestos and Mesothelioma News - July 26, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer chemotherapy chemotherapy drugs chemotherapy drugs for mesothelioma chemotherapy for mesothelioma mesothelioma treatment moffitt cancer center new chemotherapy drug Source Type: news

IMPRINT Mesothelioma Treatment Boosts Radiation Therapy
Doctors confirmed a novel radiation procedure can be combined safely and effectively with aggressive lung-sparing surgery to improve survival time and quality of life for patients with mesothelioma. After a decade of refinement, a small number of mesothelioma specialty centers now are using intensity-modulated pleural radiation therapy (IMPRINT) as part of the recent advancements in multidisciplinary treatments. “We’re hoping that all centers with experience in treating mesothelioma will now look at this as another technique to put in their arsenal,” radiation oncologist Dr. Kenneth Rosenzweig of the Moun...
Source: Asbestos and Mesothelioma News - July 15, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer treatments IMPRINT for mesothelioma lung cancer treatments mesothelioma treatment pleural mesothelioma radiation for mesothelioma radiation therapy Source Type: news

IMPRINT Mesothelioma Treatment Boosts Radiation Therapy
Doctors confirmed a novel radiation procedure can be combined safely and effectively with aggressive lung-sparing surgery to improve survival time and quality of life for patients with mesothelioma. After a decade of refinement, a small number of mesothelioma specialty centers now are using intensity-modulated pleural radiation therapy (IMPRINT) as part of the recent advancements in multidisciplinary treatments. “We’re hoping that all centers with experience in treating mesothelioma will now look at this as another technique to put in their arsenal,” radiation oncologist Dr. Kenneth Rosenzweig of the Moun...
Source: Asbestos and Mesothelioma News - July 15, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer treatments IMPRINT for mesothelioma lung cancer treatments mesothelioma treatment pleural mesothelioma radiation for mesothelioma radiation therapy Source Type: news

ONCOS-102 Mesothelioma Clinical Trial Promises Hope
Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases. The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses. Researchers are administering the immunotherapy drug as first-line therapy in combination with chemotherapy using pemetrexed and cisplatin. “Based on what we’ve seen in our first study of patients with various solid tumor types, which is good tolerance and response in a couple ...
Source: Asbestos and Mesothelioma News - July 12, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: immunotherapy clinical trial immunotherapy for cancer mesothelioma mesothelioma clinical trials mesothelioma immunotherapy ONCOS 102 Source Type: news

Targovax doses first patient in Phase Ib/II trial of ONCOS-102 to treat MPM
Norwegian-based immuno-oncology company Targovax has dosed the first patient in the Phase Ib/II combination trial of a combination pemetrexed and cisplatin with ONCOS-102 to treat malignant pleural mesothelioma (MPM). (Source: Drug Development Technology)
Source: Drug Development Technology - July 3, 2016 Category: Pharmaceuticals Source Type: news

German Supreme Court Grants Lilly Appeal in Alimta(R) Vitamin Regimen Patent Lawsuit
Alimta Case Returned to Court of Appeal for New Ruling INDIANAPOLIS, June 14, 2016 -- (Healthcare Sales & Marketing Network) -- The German Federal Supreme Court has granted the appeal by Eli Lilly and Company (LLY) in the case of Eli Lilly and Company ... Biopharmaceuticals, Generics, LitigationEli Lilly, Actavis, Alimta , pemetrexed (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2016 Category: Pharmaceuticals Source Type: news

Canadian Doctors Test Pemetrexed in Mesothelioma HIPEC Treatment,...
Researchers say the mesothelioma drug has potential for use in heated chemotherapy technique.(PRWeb June 04, 2016)Read the full story at http://www.prweb.com/releases/2016/06/prweb13461333.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 4, 2016 Category: Pharmaceuticals Source Type: news

Alimta (Pemetrexed) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 19, 2016 Category: Drugs & Pharmacology Source Type: news

Immunotherapy Vaccine for Mesothelioma Gets High Marks
Immunotherapy vaccine CRS-207 is moving closer to changing the way malignant pleural mesothelioma will be treated in the future. CRS-207 produced a startling 94 percent disease control rate when combined with a chemotherapy cocktail of cisplatin and pemetrexed in a recent, multicenter clinical trial. Thoracic oncologist Dr. Thierry Jahan of the UCSF Helen Diller Family Comprehensive Cancer Center detailed the results last week at the 2016 European Lung Cancer Conference. “We’ve seen a really impressive response,” Jahan said. “It’s an impressive signal for a study like this.” ...
Source: Asbestos and Mesothelioma News - May 3, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

New Case Report Illustrates Power of “Maintenance Therapy” for...
Chinese researchers say administering a maintenance dose of the mesothelioma drug pemetrexed produced a “perfect response” in an advanced mesothelioma patient.(PRWeb April 12, 2016)Read the full story at http://www.prweb.com/releases/2016/04/prweb13330247.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 12, 2016 Category: Pharmaceuticals Source Type: news

New Mesothelioma Immunogene Clinical Trial Set to Launch
For more than a decade, pulmonologist Dr. Dan Sterman has believed immunotherapy would become the catalyst for major advancements in the treatment of malignant pleural mesothelioma. Today, he is closer than ever to proving that point. Sterman, director of pulmonary medicine at New York University, soon will help launch a multicenter clinical trial involving a powerful immunogene therapy combination that may change the way this deadly asbestos-related cancer is viewed. “I believe that immunotherapy will become the fourth pillar of treatment for mesothelioma (joining chemotherapy, radiation and surgery),&rdquo...
Source: Asbestos and Mesothelioma News - March 22, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

New Mesothelioma Clinical Trial Hopes to Improve Chemotherapy
This study is part of a broad development program that includes a number of additional planned studies." TRACON Pharmaceuticals develops novel targeted cancer therapies. Its TRC105 antibody is directed at renal cell carcinoma and hepatocellular carcinoma. This clinical trial with TRC102 is one of five nationally involving methoxyamine, but one of more than 200 trials for mesothelioma. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - January 27, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA® (pemetrexed for injection) and Merck’s KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-l...
Source: Merck.com - Research and Development News - November 19, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Lilly Says Court Ruled in its Favor on Patent
Eli Lilly & Co. said a federal court ruled that generic products proposed by a Teva Pharmaceutical Industries Ltd. unit would infringe a U.S. patent for the drug maker’s blockbuster cancer drug Alimta. (Source: WSJ.com: Health)
Source: WSJ.com: Health - August 25, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news

Eli Lilly wins UK Alimta drug patent case on appeal, shares jump
LONDON (Reuters) - Eli Lilly has won a patent case in the Court of Appeal in London over its blockbuster Alimta lung cancer drug, boosting prospects for future sales and dealing a blow to generic challenger Actavis, now renamed Allergan. (Source: Reuters: Health)
Source: Reuters: Health - June 25, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Bevacizumab May Be Next Standard of Care for Mesothelioma
Discussions About Mesothelioma at ASCO Meeting There were other abstracts involving mesothelioma presented at the ASCO, adding even more optimism about potential treatment advances. Dr. Raffit Hassan, mesothelioma specialist from the National Cancer Institute, detailed results of a phase I trial involving immunotherapy drug CRS-207 in combination with standard chemotherapy. Disease control was obtained in 30 of the 32 trial participants. There was partial response in 19 patients and stable disease in 11. CRS-207 is given by vaccination. Median duration of response was 5 months and median progression-free survi...
Source: Asbestos and Mesothelioma News - June 5, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Collaborative group phase III study shows Roche’s Avastin improves survival in patients with mesothelioma - a devastating type of thoracic cancer
Roche announced today phase III results from a collaborative group study that showed that patients with malignant pleural mesothelioma, a rare type of cancer that affects the lining of the lungs, lived significantly longer when treated with Avastin in combination with standard therapy (pemetrexed and cisplatin chemotherapy) compared to standard therapy alone. (Source: Roche Investor Update)
Source: Roche Investor Update - May 30, 2015 Category: Pharmaceuticals Source Type: news

FDA Approves New Use for Immunotherapy Drug in Mesothelioma Treatment
The U.S. Food and Drug Administration (FDA) granted orphan drug designation last week to the immunotherapy vaccine CRS-207, moving it one step closer to changing the way malignant pleural mesothelioma is treated. CRS-207 is derived from Listeria monocytogenes, a bacterium that causes the serious infection listeriosis. For the vaccine, the bacteria are weakened and genetically modified to produce an anti-tumor response without causing disease. Early results are impressive. The vaccine produced a 94 percent rate of disease control, either partial response or stable disease, according to a presentation made at the latest Inte...
Source: Asbestos and Mesothelioma News - April 7, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Eli Lilly loses Alimta drug patent case in Germany to Actavis
(Reuters) - Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine. (Source: Reuters: Health)
Source: Reuters: Health - March 6, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Merrimack begins Phase II trial of MM-121 to treat patients with heregulin positive NSCLC
US-based Merrimack Pharmaceuticals has started a Phase II clinical trial of its fully human monoclonal antibody, MM-121, in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone to treat patients with heregulin positive, local… (Source: Drug Development Technology)
Source: Drug Development Technology - February 20, 2015 Category: Pharmaceuticals Source Type: news

New Stem Cell Trial Fuels Hopes for Mesothelioma Treatment
Early results from an international clinical trial involving the targeted killing of mesothelioma stem cells are better than anticipated, fueling considerable hope for the future of treatment. The phase II trial of the drug defactinib (VS-6063) currently includes 180 patients enrolled at 55 sites in 13 countries. Verastem, Inc., a relatively small biopharmaceutical company based in the Boston area, markets the drug. The drug also is being tested - with equally encouraging results - for ovarian and non-small-cell lung cancers. "We're onto something really important here," Verastem president and Chief Financial ...
Source: Asbestos and Mesothelioma News - January 16, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer
Dateline City: KENILWORTH, N.J. & INDIANAPOLIS Combinations of KEYTRUDA® (pembrolizumab) with Alimta® (pemetrexed), Cyramza® (ramucirumab), or necitumumab to be explored KENILWORTH, N.J. & INDIANAPOLIS--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compo...
Source: Merck.com - Research and Development News - January 13, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news

French Study Warns of Little-known Side Effect from Mesothelioma Drug,...
French researchers say doctors treating mesothelioma patients with pemetrexed should watch out for a potentially-serious but often-unrecognized side effect.(PRWeb January 05, 2015)Read the full story at http://www.prweb.com/releases/2015/01/prweb12422010.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 6, 2015 Category: Pharmaceuticals Source Type: news

Vegetable Compound May Reduce Mesothelioma Treatment Side Effects
For a cancer as rare and difficult to treat as mesothelioma, innovative thinking is vital to making progress that helps survivors live longer and feel healthier. While experimental therapies for this disease have harnessed genetically modified viruses, leopard frog eggs and laser-activated drugs, innovation doesn’t always come from exotic sources. Sometimes treatment breakthroughs are hiding in plain sight. Take the veggies on your dinner plate, for example. A research team has reported an anti-cancer vegetable compound called PEITC could have interesting therapeutic benefits for pleural mesothelioma patients. The ...
Source: Asbestos and Mesothelioma News - December 9, 2014 Category: Environmental Health Authors: Joey Rosenberg Tags: Treatment & Doctors Source Type: news

New Drug Ofev Gaining Momentum in Fight Against Mesothelioma
Mesothelioma patients battling shortness of breath — a symptom that makes everyday activities increasingly difficult — may soon find relief with nintedanib, a new anti-cancer drug shown to relieve respiratory distress. Nintedanib recently received approval from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), a lung scarring condition with similarities to asbestosis. German-based drugmaker Boehringer Ingelheim markets the drug under the brand name Ofev. The European Commission also granted the marketing of the drug as Vargatef for use with docetaxel to combat...
Source: Asbestos and Mesothelioma News - December 8, 2014 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

Customizing chemotherapy in lung cancer: New phase II data reported
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown. In a randomized phase II study, researchers showed that patients whose lung cancers expressed low levels of an enzyme called thymidylate synthase experienced a greater benefit from treatment with the combination of pemetrexed and cisplatin than those whose tumors expressed high levels. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 27, 2014 Category: Science Source Type: news

Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca
(European Society for Medical Oncology) The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 27, 2014 Category: Biology Source Type: news

Georgia Regents University Launches Immunotherapy Clinical Trial
The Georgia Regents University Cancer Center, a national leader in immunotherapy research, has opened its first clinical trial for mesothelioma patients. The Phase 2 trial is open to patients with unresectable peritoneal or pleural mesothelioma, providing a promising new treatment option for this rare and aggressive cancer. Immunotherapy involves triggering the body's own immune system to identify and destroy the cancer cells without harming the healthy ones. This multicenter trial will study the drug tremelimumab, which has shown an ability to stimulate the immune system and attack tumors. It already has shown potential ...
Source: Asbestos and Mesothelioma News - September 22, 2014 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news